Zimmer Biomet (NYSE:ZBH) Now Covered by Leerink Partners

Leerink Partners started coverage on shares of Zimmer Biomet (NYSE:ZBH) in a report published on Monday morning,Benzinga reports. The brokerage issued a market perform rating and a $101.00 price objective on the medical equipment provider’s stock.

Other analysts also recently issued reports about the stock. Evercore upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $94.00 to $120.00 in a research report on Monday, January 5th. Weiss Ratings upgraded shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, April 7th. BTIG Research reiterated a “neutral” rating on shares of Zimmer Biomet in a research report on Monday, March 23rd. The Goldman Sachs Group downgraded shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective on the stock. in a research report on Friday, January 9th. Finally, William Blair began coverage on shares of Zimmer Biomet in a research report on Friday, February 20th. They issued a “market perform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $105.95.

Zimmer Biomet Trading Up 2.4%

NYSE ZBH opened at $95.35 on Monday. Zimmer Biomet has a one year low of $84.59 and a one year high of $108.29. The company has a 50-day simple moving average of $93.11 and a 200-day simple moving average of $93.33. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. The firm has a market capitalization of $18.46 billion, a PE ratio of 26.93, a price-to-earnings-growth ratio of 1.90 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, beating the consensus estimate of $2.38 by $0.04. The business had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the business posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, equities analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s payout ratio is 27.12%.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the business’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the sale, the senior vice president directly owned 10,224 shares in the company, valued at approximately $967,803.84. The trade was a 20.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.39% of the company’s stock.

Institutional Trading of Zimmer Biomet

A number of hedge funds and other institutional investors have recently made changes to their positions in ZBH. Dodge & Cox raised its holdings in shares of Zimmer Biomet by 1.3% in the 4th quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock worth $2,113,736,000 after purchasing an additional 290,676 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Zimmer Biomet by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock worth $2,111,658,000 after purchasing an additional 192,517 shares in the last quarter. State Street Corp raised its holdings in shares of Zimmer Biomet by 2.3% in the 4th quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock worth $795,814,000 after purchasing an additional 195,214 shares in the last quarter. Capital International Investors raised its holdings in shares of Zimmer Biomet by 11.5% in the 3rd quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after purchasing an additional 778,467 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Zimmer Biomet by 43.2% in the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after acquiring an additional 2,017,857 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.